Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 6/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280959 | 1.00 | FGFR1 (0.33) | FGFR1NPC1ALDH1A1LMNAPOLB | |
| SCHEMBL5249325 | 0.84 | KDR (0.37) | FGFR1NPC1LMNAKDRLCK | |
| SCHEMBL5249331 | 0.84 | KDR (0.37) | FGFR1NPC1LMNAKDRLCK | |
| SCHEMBL6709435 | 0.82 | FGFR1 (0.35) | FGFR1NPC1RAB9A | |
| SCHEMBL6709438 | 0.82 | FGFR1 (0.35) | FGFR1NPC1RAB9A | |
| SCHEMBL7225599 | 0.81 | KDR (0.38) | FGFR1ALDH1A1LMNAPOLBKDR | |
| SCHEMBL5252046 | 0.77 | KDR (0.46) | FGFR1NPC1KDRLCK | |
| SCHEMBL5252041 | 0.77 | KDR (0.46) | FGFR1NPC1KDRLCK | |
| SCHEMBL7554327 | 0.73 | KDR (0.45) | FGFR1KDRLCK | |
| SCHEMBL7554330 | 0.73 | KDR (0.45) | FGFR1KDRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6891044-B2 | Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-05-10 | — | — | US | disclosed |